MediWound Ltd - Company Profile
Powered by 
All the sales intelligence you need on MediWound Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how MediWound Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with MediWound Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
MediWound Ltd (MediWound) is a biopharmaceutical company. It is focused on developing enzymatic therapeutics for non-surgical tissue repair. The company’s product portfolio includes NexoBrid, a topical biological agent that uses bromelain-enriched proteolytic enzymes to remove nonviable burn tissue in deep partial and full-thickness thermal burns. MediWound is advancing EscharEx, a multimodal therapy for chronic wounds, currently in Phase II trials, with a Phase III study for venous leg ulcers planned. The company is also developing MW005, a topical drug for low-risk basal cell carcinoma, which has shown promising initial results in Phase I/II trials. MediWound is headquartered in Yavne, Israel.
Headquarters
Israel
Address
42 Hayarkon Street, Yavne, 8122745
Website
www.mediwound.com
Telephone
972 77 9714100
No of Employees
121
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
MDWD (NASD)
Revenue (2025)
$17.0M
-16.1%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
21%
(2025 vs 2024)
Market Cap*
$190.5M
Net Profit Margin (2025)
XYZ
5.8%
(2025 vs 2024)
* As of and is in US$
MediWound Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Enzymatic Therapeutics | NexoBrid |
| Bioactive Multimodal Debridement Therapy | EscharEx |
| Pipeline: | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In August, the company received the US Food and Drug Administration's approval of NexoBrid for the treatment of pediatric patients with severe thermal burns. |
| 2024 | Others | In July, the company announced to be acquired by Solventum for US$400 million. |
| 2023 | Contracts/Agreements | In October, the company entered into an agreement with 3M Health Care to provide its two-layer compression systems Coban 2 and Coban 2 Lite. |
Competitor Comparison
| Key Parameters | MediWound Ltd | Smith & Nephew Plc | ConvaTec Group Plc | Molnlycke Health Care AB | Avita Medical Inc |
|---|---|---|---|---|---|
| Headquarters | Israel | United Kingdom | United Kingdom | Sweden | United States of America |
| City | Yavne | Watford | London | Gothenburg | Valencia |
| State/Province | - | England | Greater London | Vastra Gotaland | California |
| No. of Employees | 121 | 17,349 | 10,903 | 8,617 | 226 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Nachum Shamir | Chairman | Executive Board | 2022 | 71 |
| Ofer Gonen | Chief Executive Officer | Senior Management | 2022 | 53 |
| Hani Luxenburg | Chief Financial Officer | Senior Management | 2023 | 53 |
| Shmulik Hess, Ph.D | Chief Commercial Officer; Chief Operating Officer | Senior Management | 2023 | 53 |
| Ety Klinger, Ph.D. | Chief Medical Officer | Senior Management | 2014 | 64 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer